Form 8-K - Current report:
SEC Accession No. 0001600620-24-000106
Filing Date
2024-11-07
Accepted
2024-11-07 06:13:58
Documents
16
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K auph-20241107.htm   iXBRL 8-K 38306
2 EX-99.1 exhibit991_q32024earningsr.htm EX-99.1 172705
3 EX-99.2 exhibit992_pressreleasebod.htm EX-99.2 7327
7 aurinalogo.jpg GRAPHIC 11010
  Complete submission text file 0001600620-24-000106.txt   372809

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20241107.xsd EX-101.SCH 1813
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20241107_lab.xml EX-101.LAB 21629
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20241107_pre.xml EX-101.PRE 12532
18 EXTRACTED XBRL INSTANCE DOCUMENT auph-20241107_htm.xml XML 2720
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 241432939
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)